Xeltis is a clinical-stage medtech company with the world's most advanced polymer-based platform of restorative cardiovascular devices.
Xeltis has raised $13.6M in total funding. The most recent round was Series D. The last funding was announced in August 2023.
Xeltis's investors include European Investment Bank, Kurma Partners, Invest-NL, EQT Life Sciences, Ysios Capital.
Xeltis is headquartered in Eindhoven, The Netherlands.
Xeltis is a clinical-stage medtech company with the world's most advanced polymer-based platform of restorative cardiovascular devices.
Xeltis is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Xeltis — Funding & Investors." VCBacked, August 14, 2023, https://www.vcbacked.co/company/xeltis. Accessed July 20, 2026.
VCBacked. (2023). Xeltis — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/xeltis
{{cite web |title=Xeltis — Funding & Investors |url=https://www.vcbacked.co/company/xeltis |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated